

ABBREVIATED CURRICULUM VITAE

04-10-03

NAME: Sheldon Harrison Preskorn, M.D.
CITIZENSHIP: United States of America
MEDICAL SCHOOL: University of Kansas, Kansas City, Kansas (M.D., 1974)
WEBSITE: www.preskorn.com

POSTGRADUATE:

Pathology Residency,
University of Kansas Medical Center (UKMC) Kansas City, Kansas, 1973-75
Rotating Internship, Internal Medicine/Psychiatry
UKMC, Kansas City, Kansas, 1975-76
Psychiatry Residency,
Washington University School of Medicine, St. Louis, Missouri, 1976-78

ACADEMIC APPOINTMENTS:

Professor and Chairman, Department of Psychiatry and Behavioral Sciences,
University of Kansas School of Medicine (UKSM), Wichita, Kansas, 1999 -
Professor and Vice Chairman, Department of Psychiatry,
UKSM, Wichita, Kansas, 1985-99
Professor of Psychiatry and Pharmacology,
Washington University School of Medicine, St. Louis, Missouri, 1984-85
Associate Professor of Psychiatry and Pharmacology Toxicology & Therapeutics,
UKSM, Kansas City, Kansas, 1981-84
Assistant Professor of Psychiatry and Pharmacology Toxicology & Therapeutics,
UKSM, Kansas City, Kansas, 1978-81
Assistant Instructor in Psychiatry,
Washington University School of Medicine, St. Louis, Missouri, 1976-78

DIRECTORSHIP POSITIONS:

Medical Director, Clinic Research Unit, 1990-
President and Medical Director, Psychiatric Research Institute,-
Via Christi Regional Medical Center, Wichita, Kansas, 1987 -
Director, Outpatient Clinic Department of Psychiatry,
UKSM, Wichita, Kansas, 1991-99
Chief, Psychiatry Service,
Wichita Veterans Administration Medical Center, Wichita, Kansas, 1985-91

LICENSURE:

Permanent Kansas Medical License # 4-6344
Permanent Missouri Medical License # 00101337

CONSULTANTSHIP:

Menninger Foundation, Topeka, Kansas, 1992-98.

AWARDS:

Foxington *Who's Who Directory of Executives and Professionals*, 2000
National Registry of Who's Who, Life Member, 2000
The Best Doctors in America, 4th Edition, 1998
American Psychiatric Association, Nancy C.A. Roeske, M.D.,
Certificate of Excellence in Medical Student Education, 1998
National Alliance for the Mentally Ill, Exemplary Psychiatrist Award, 1993
The Mental Health Association in Kansas, 1989
Alliance for Mentally Ill in Sedgwick County, 1988
Research Scientist Development Award (NIMH), 1980-1985
American Academy of Clinical Psychiatry, Clinical Research Award, 1984
University of Kansas College of Health Sciences Research Award, 1983
American Academy of Clinical Psychiatry Annual Research Award, 1982
A.E. Bennett Neuropsychiatric Research Foundation Award, 1978
Roche Laboratory Award for Neuroscience, 1978
Mead-Johnson Award for Overall Excellence in Research, 1978
Walter C. Menninger Neuropsychiatry Award, 1978
Outstanding Young Men of America, 1977 and 1982
KUMC Psychiatric Housestaff Research Award, 1976
KUMC Pathology Housestaff Research Award, 1975
Chester M. Goodwin Award for Neurological Research, 1971
Who's Who in American Colleges and Universities, 1969

FELLOWSHIPS:

Maurice Falk Fellowship, 1975-78
University of Kansas Research Fellowship, 1971
Wichita State University Research Assistantship, 1970
Wichita State University Honors Fellowship, 1969-70

CERTIFICATION:

Psychiatry plus Geriatric qualifications, American Board of Psychiatry and Neurology, 1997
Diplomate, American Board of Psychiatry and Neurology, 1981
Diplomate, National Board of Medical Examiners, 1975

EDITORIAL BOARDS:

Associate Editor, *Journal of Clinical Psychiatry*, 2001
Associate Editor, *Journal of Clinical Psychopharmacology*, 2000
Contributing Editor, *Journal of Psychiatric Practice*, (formerly JPPBH) 2000 -
Contributing Editor, *Journal of Practical Psychiatry and Behavioral Health*, 1995-99
American Hospital Formulary Service Drug Information, 1998
Associate Editor, *Journal of Clinical Psychiatry*, 1978-88

MAJOR RESEARCH INTEREST:

Psychopharmacology, affective and anxiety disorders, neuroscience.

GRANTS: Continuous funding since 1978. Supplemental report available.

REVIEWER FOR SCIENCE:

American Hospital Formulary Service Drug Information Monographs

American Journal of Geriatric Psychiatry

American Journal of Primatology

American Journal of Psychiatry

American Society of Pharmacology and Experimental Therapeutics

Annals of Pharmacotherapy

Archives of General Psychiatry

Biological Psychiatry

Bipolar Disorders

Canadian Psych Research Foundation

Clinical Pharmacokinetics

CNS Drugs

Currents in Affective Illness

Depression and Anxiety

Drug and Aging Journal

Drug Evaluations

Drugs

European Journal of Pharmacology

General Hospital Psychiatry

Geriatric Agitation Guidelines

Geriatric Psychiatry

Int'l Journal of Neuropsychopharmacology

Int'l Journal of Neuropsychiatry

Int'l Journal of Psychiatry in Medicine

Journal of Affective Disorders

Journal of Clinical Psychiatry

Journal of Clinical Psychopharmacology

Journal of Neuropsychiatry & Clinical Neurosciences

Journal of Pharmaceutical Sciences

Journal of Pharmacy Technology

Journal of Practical Psychiatry & Behavioral Health

Journal of Psychopharmacology

Journal of the American Medical Association

Life Sciences

Neuropsychopharmacology

Pharmacoeconomics

Psychiatric Times

Psychometrics

Psychopharmacology

Therapeutics Bulletin

REVIEW COMMITTEES:

Panel Member, Center for Scientific Review, NIMH Special Emphasis Panel, 1999 -
Member, Via Christi Regional Medical Center, Institutional Review Board, 1989 -
Panel Member, Center for Scientific Review, NIH Study Sect.-Genetic Sciences, 1999
Member, International Advisory Board for the Guidelines in Depression, 1998–2000
Moderator- Faculty, AMERICAN PSYCHIATRIC ASSOCIATION. Physician Awareness
Program, 1987-89
Reviewer (Member), Wesley Foundation Scientific Advisory Panel, 1987-1989
Reviewer (ad hoc), Nat'l Inst. Neurological & Communicative Disorders & Stroke (NINCDS) study
section on Spinal Cord Trauma Centers, 1983 and 1987
Reviewer (ad hoc) National Science Foundation Neuropharmacology Section, 1983-87
Reviewer (ad hoc), NIMH Psychopharmacological, Biological, and Physical Treatments
Research Review Committee (TDA2), 1986
Member, FDA Psychopharmacologic Drugs Advisory Committee, 1982-86
Reviewer (ad hoc), VA Merit Rev. Mental Health & Behavioral Science Comm., 1985
Reviewer (ad hoc), NIMH Mental Health Behavioral Science Research Review 1984

SOCIETIES:

American Psychiatric Association, Member, 1979; Fellow, 1987, Distinguished Fellow, 2003
International Society for Affective Disorders, 2001-02
American Psychopathological Association, Fellow, 1989
Society of Neuroscience, Member 1978; President 1981-82; Local Chapter Secretary/
Treasurer 1980
American Society of Clinical Pharmacology and Therapeutics, Member, 1979
Society of Biological Psychiatry, Member, 1978
Alpha Omega Alpha, Member, 1973
American Medical Association, Member 1971
Phi Kappa Phi, Member, 1970
Omicron Delta Kappa, President, 1969
Wichita State University Honors Society, Member 1969

ORGANIZATIONAL OFFICES:

Member, Sedgwick County Task Force on Suicide Prevention, 2001 -
Scientific Advisor, MHA of So. Central Kansas, 2001 -
NIMH Outreach & Education, 2000 -
Sedgwick County Alliance for Mentally Ill, 1996 -
Advisory Committee, Kansas Alliance for the Mentally Ill, 1993 -
Member, Board of Directors, Project Awareness for Major Mental Illness, 1990 -
Founding President, Project Awareness for Major Mental Illness, 1990 -
Member, University of Kansas School of Medicine Research Committee, 1992-94
Member, Scientific Program Committee for American Society of Clinical Pharmacology and
Therapeutics, 1983-85
Chairman, KUMC Faculty & Student Affairs Committee, 1983-84
Member, Governor's Advisory Commission on Mental Health and Retardation Services and
Community Mental Health Programs, State of Kansas, 1979-84
Member, KUMC Human Studies Research Committee, 1979-84
Member, Continuing Education Committee for Kansas Psychiatric Society, 1980-82
Chairman, Subcommittee on New Research, 1980-82
Member, American Psychiatric Association Program Committee (Nat'l), 1978-82
Member, KUMC Peer Utilization Review Committee, 1978-80
Member, American Psychiatric Association Task Force Tardive Dyskinesia, 1976-79
Member, American Psychiatric Association Council-Research & Development, 1976-78
Representative, KUMC Housestaff Association, 1976
Representative, Association of American Medical Colleges, 1971-73
Treasurer, KUMC Chapter (student) of the KS Medical Society, 1970-71
President/Administrative/Executive Coordinator, WSU Student Union Activities Board, 1969-70
Educational/Cultural Coordinator, WSU Student Union Activities Board, 1968-69
Chairman, Wichita Film Society, 1967-68

VISITING PROFESSOR/LECTURER:

Presented at meetings and/or universities in the following locations on one or more occasions:

INTERNATIONAL LOCATIONS

Brisbane, Australia	Athens, Greece
Melbourne, Australia	Rhodes, Greece
Sydney, Australia	Budapest, Hungary
Tasmania, Australia	Jerusalem, Israel
Vienna, Austria	Cagliari, Italy
Brussels, Belgium	Florence, Italy
Hamilton, Bermuda	Palermo, Italy
Rio de Janeiro, Brazil	Rome, Italy
Halifax, Canada	Venice, Italy
Hamilton, Canada	Kyoto, Japan
London, Canada	Seoul, Korea
Montreal, Canada	Mexico City, Mexico
Toronto, Canada	Acapulco, Mexico
Saskatchewan, Canada	Monte Carlo, Monaco
Vancouver, Canada	Amsterdam, Netherlands
Winnipeg, Canada	Auckland, New Zealand
Beijing, China	Oslo, Norway
Hong Kong, China	Trondheim, Norway
Shanghai, China	Tromso, Norway
Copenhagen, Denmark	Las Croabas, Puerto Rico
Odense, Denmark	San Juan, Puerto Rico
Alexandria, Egypt	Glascow, Scotland
Cairo, Egypt	Capetown, South Africa
London, England	Johannesburg, South Africa
Cannes, France	Badojoz, Spain
Nice, France	Barcelona, Spain
Paris, France	Madrid, Spain
Berlin, Germany	Linkoping, Sweden
Dresden, Germany	Lund, Sweden
Frankfurt, Germany	Stockholm, Sweden
Giessen, Germany	Basel, Switzerland
Hamburg, Germany	Berne, Switzerland
Hannover, Germany	Geneva, Switzerland
Marburg, Germany	Lausanne, Switzerland
Muenster, Germany	Zurich, Switzerland
Tuebingen, Germany	

UNITED STATES OF AMERICA

University of Alabama-Birmingham	University of Missouri-Kansas City
University of Southern Alabama	Tulane University
University of Arkansas	University of Mississippi
University of Arizona	Duke University
Loma Linda University	East Carolina University
Stanford University	Vanderbilt University
University of California-Davis	University of North Dakota
University of California-Irvine	Creighton University
University of California-LA	University of Nebraska
University of California-Sacramento	University of New Jersey Dental
University of California-San Francisco	University of Nevada
University of Southern California	Columbia University
University of Connecticut-Institute of Living	Cornell University
Yale University	New York University
George Washington University	State University of New York-Albany
Howard University	State University of New York-Buffalo
University of Miami	State University of New York-Stony Brook
University of South Florida	Case Western Reserve University, OH
University of Hawaii	Cleveland Clinic
Chicago University	Medical College of Ohio
Loyola University	Ohio State University
Northwestern University	University of Ohio
Purdue University	Oklahoma Department of Mental Health
Rush Presbyterian University	University of Oklahoma
Southern Illinois University	University of Oregon
Menninger Foundation	Thomas Jefferson University
Wichita State University	University of Pennsylvania
Boston University	University of Pittsburg
Harvard University-Beth Israel Hospital	Bowman-Grey University
Harvard University-Mass. Mental Health Center	Medical College of South Carolina
Harvard University-McLean Hospital	University of South Carolina-Columbia
Massachusetts General Hospital	University of South Dakota
Tufts University	University of Tennessee
John Hopkins University	Southwestern Medical College-Dallas
Henry Ford Hospital-Detroit	University of Texas-Galveston
University of Michigan	University of Texas-San Antonio
Wayne State University	University of Utah
Mayo Clinic	University of Virginia
University of Minnesota	University of Vermont
St. Louis University	University of Wisconsin
University of Missouri-Columbia	University of Wisconsin Medical College
Washington University	University of Wisconsin-Madison
	University of Wisconsin-Milwaukee

SUMMARIZED PUBLICATIONS:

Publications total over 350, including over 200 journal articles, over 40 book chapters, 8 books and over 50 abstracts. Principal topics have been basic and clinical psychopharmacology, with an emphasis on psychopharmacology and neurosciences.

ITEMIZED PUBLICATIONS: (abbreviated CV only contains publications since 1997)

JOURNAL ARTICLES:

1. Preskorn S: Selection of an antidepressant: Mirtazapine. *Journal of Clinical Psychiatry* 58(6):3-8, 1997. (RM#2732)
2. Preskorn S: Foreward. *Journal of Clinical Pharmacokinetics* 32(suppl 1):0, 1997. (RM#4112)
3. Preskorn S: Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. *Journal of Clinical Pharmacokinetics* 32(suppl 1):1-21, 1997. (RM#1214)
4. Tremaine L, Wilner K, Preskorn S: A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. *Journal of Clinical Pharmacokinetics* 32(suppl 1):31-36, 1997. (RM#1873)
5. Gardner M, Baris B, Wilner K, Preskorn S: Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. *Journal of Clinical Pharmacokinetics* 32(suppl 1):43-49, 1997. (RM#230)
6. Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism *in vivo*. *Psychopharmacology Bulletin* 33(4):659-665, 1997. (RM#2127)
7. Alderman J, Preskorn S, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. *Journal of Clinical Psychopharmacology* 17;(4):284-291, 1997. (RM#1848)
8. Preskorn S. Pharmacotherapeutic profile of venlafaxine. *European Psychiatry* 12(S4):285-294, 1997. (RM#2812)
9. Preskorn S, Harvey A, Stanga C. Drug interactions and their role in patient care. *Current Review of Mood and Anxiety Disorders* 1, 203-214, 1997. (RM#2345)
10. Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. *The Annals of Pharmacotherapy* 32(4):432-436, 1998. (RM#2449)

11. Preskorn SH, Catterson M. Antidepressants and the elderly: Focus on newer agents. *International Journal of Geriatric Psychopharmacology* 1:66-77, 1998. (RM#2725)
12. Preskorn SH. Debate resolved: There are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. *Journal of Psychopharmacology* 12(3)(suppl B):S89-S97, 1998. (RM#2729)
13. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion. *Journal of Affective Disorders* 51:237-254, 1998. (RM#2816)
14. Horst WD, Preskorn SH. The pharmacology and mode of action of venlafaxine. *Review of Contemporary Pharmacotherapy* 9:293-302, 1998. (RM#2731)
15. Preskorn SH. Antidepressant options in primary care. *Clinical Cornerstone* 1(4):31-55, 1999. (RM#2996)
16. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice. *Clinical Pharmacokinetics* 37(2):147-165, 1999. (RM#2991)
17. Catterson M, Martin RL, Preskorn SH. Psychopharmacologic drug-drug interactions in the elderly. *Clinical Geriatrics* 7(9):46-54, 1999. (RM#3201)
18. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine in healthy male volunteers. *Archives of General Psychiatry* 57(5):503-509, 2000. (RM#3918)
19. Shad MU, Marsh C, Preskorn SH. The economic consequences of a drug-drug interaction. *Journal of Clinical Psychopharmacology* 21(1):119-20, 2001. (RM#4137)
20. Findling RL, Marcus RN, D'Amico F, Reed MD, Preskorn SH, Magnus RD, Marathe P. Nefazodone pharmacokinetics in depressed children and adolescents. *Journal of the American Academy of Child and Adolescent Psychiatry* 39(8):1008-1016, 2000. (RM#3458)
21. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. *Journal of Clinical Psychopharmacology* 21(2):161-166, 2001. (RM#4936)
22. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M. Efficacy and safety in mirtazapine in depressed patients after SSRI treatment failure: An open-label trial. *Journal of Clinical Psychiatry* 62(6):413-420, 2001. (RM#5005)

23. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild A, Snavely D, Ghosh K, Ball W, Reines S, and SPA Depression Study Group. Demonstration of the efficacy and safety of a novel substance P(NK1) receptor antagonist (SPA) in major depression. Clinical Neuropharmacology Submitted Sep 15, 2002. (RM#5008)
24. Werder SF, Preskorn SH. Managing polypharmacy walking the fine line. Current Psychiatry Submitted Jan 1, 2002. (RM#7290)

COLUMNS:

1. Preskorn S: Let the data speak to you. Journal of Practical Psychiatry and Behavioral Health 3(1):45-48, 1997. (RM#2053)
2. Preskorn S: Do you believe in magic? Journal of Practical Psychiatry and Behavioral Health 3(2):99-103, 1997. (RM#2198)
3. Preskorn S: Patients don't fail treatments, treatments fail patients. Journal of Practical Psychiatry and Behavioral Health 3(3):165-168, 1997. (RM#2259)
4. Preskorn S: The appearance of knowledge. Journal of Practical Psychiatry and Behavioral Health 3(4):233-238, 1997. (RM#2351)
5. Preskorn S: I don't see 'em. Journal of Practical Psychiatry and Behavioral Health 3(5):302-307, 1997. (RM#2342)
6. Preskorn S: Pandora's Box: Pregnancy and antidepressants. Journal of Practical Psychiatry and Behavioral Health 3(6):363-365, 1997. (RM#2352)
7. Preskorn S: Do you feel lucky? Journal of Practical Psychiatry and Behavioral Health 4(1):37-40, 1998. (RM#2437)
8. Preskorn S: Marooned, only one choice. Journal of Practical Psychiatry and Behavioral Health 4(2):110-114, 1998. (RM#2451)
9. Preskorn S. 11.2 billion dollars: Is it worth it? Journal of Practical Psychiatry and Behavioral Health 4(3):163-168, 1998. (RM2728)
10. Preskorn S: A message from Titanic. Journal of Practical Psychiatry and Behavioral Health 4(4):236-241, 1998. (RM#2727)
11. Preskorn S: Sweetness. Journal of Practical Psychiatry and Behavioral Health 4(5):304-308, 1998. (RM#2726)
12. Preskorn S: What happened to Tommy? Journal of Practical Psychiatry and Behavioral Health 4(6):363-367, 1998. (RM#3055)

13. Preskorn, S: The slippery slide. *Journal of Practical Psychiatry and Behavioral Health* 5(1):50-55, 1999. (RM#3056)
14. Preskorn, S: Finding the signal through the noise: The use of surrogate markers. *Journal of Practical Psychiatry and Behavioral Health* 5(2):104-109, 1999. (RM#2800)
15. Preskorn, S: A tale of two patients. *Journal of Practical Psychiatry and Behavioral Health* 5(3):160-164, 1999. (RM#2853)
16. Preskorn, S: Defining "is." *Journal of Practical Psychiatry and Behavioral Health* 5(4):224-228, 1999. (RM#3057)
17. Preskorn, S: De-spinning *in vitro* data. *Journal of Practical Psychiatry and Behavioral Health* 5(5):283-287, 1999. (RM#3160)
18. Preskorn, S: Two in one: The venlafaxine story. *Journal of Practical Psychiatry and Behavioral Health* 5(6):346-350, 1999. (RM#3159)
19. Preskorn, S: Bupropion: What mechanism of action? *Journal of Psychiatric Practice* 6(1):39-44, January 2000. (RM#3216)
20. Preskorn, S: Imipramine, mirtazapine, and nefazodone: "Multiple Targets." *Journal of Psychiatric Practice* 6(2):97-102, March 2000. (RM#3215)
21. Preskorn, S: The adverse effect of the selective serotonin reuptake inhibitors: Relationship to *in vitro* pharmacology. *Journal of Psychiatric Practice* 6(3):153-157, May 2000. (RM#4174)
22. Preskorn, S: The relative adverse effect profile of non-SSRI antidepressants: Relationship to *in vitro* pharmacology. *Journal of Psychiatric Practice* 6(4):218-223, July 2000. (RM#4372)
23. Preskorn, S: The human genome project and modern drug development in psychiatry. *Journal of Psychiatric Practice* 6(5):272-276, September 2000. (RM#4608)
24. Preskorn, S: The stages of drug development and the human genome project: Drug discovery. *Journal of Psychiatric Practice* 6(6):341-344, November 2000. (RM#4619)
25. Preskorn, S: Multiple medications, multiple considerations. *Journal of Psychiatric Practice* 7(1):48-52, January 2001. (RM#4807)
26. Preskorn, S: The human genome project and drug discovery in psychiatry: Identifying novel targets. *Journal of Psychiatric Practice* 7(2):133-137, March 2001. (RM#4928)

27. Preskorn, S: Antipsychotic drug development in the pre-human-genome era: A full circle. *Journal of Psychiatric Practice* 7(3):209-213, May 2001. (RM#5010)
28. Preskorn, S: Drug discovery in psychiatry: Drilling down on the target of interest. *Journal of Psychiatric Practice* 7(4):267-272, July 2001. (RM#5011)
29. Preskorn, S: Drug development in psychiatry and the human genome project: The explosion in knowledge and potential targets. *Journal of Psychiatric Practice* 7(5):336-340, September 2001. (RM#5138)
30. Preskorn, S: Drug development in psychiatry and genomics: From E.Coli to man. *Journal of Psychiatric Practice* 7(6):415-419, November 2001. (RM#5524)
31. Preskorn, S. Drug approvals and withdrawals over the last 60 years. *Journal of Psychiatric Practice* 8(1):41-50, January 2002. (RM#5558)
32. Preskorn S, Silkey B, Jones T. Physician perceptions of drug-drug interactions and how to avoid them. *Journal of Psychiatric Practice* 8(2):112-115, March 2002. (RM#5600)
33. Preskorn S, Baker B. The overlap of DSM-IV syndromes: Potential implications for the practice of polysychopharmacology, psychiatric drug development, and the human genome project. *Journal of Psychiatric Practice* 8(3):170-177, May 2002. (RM#5589)
34. Preskorn, S. Fatal drug-drug interactions as a differential consideration in apparent suicides. *Journal of Psychiatric Practice* 8(4):233-238, July 2002. (RM#5631)
35. Preskorn, S. Clinical pharmacology case conference: Suicide Attempt? *Journal of Psychiatric Practice* 8(5):306-310, September 2002. (RM#5746)
36. Preskorn, S. Polypharmacy in a patient with refractory major depression: Part 1: The Case. *Journal of Psychiatric Practice* 8(6), November 2002. (RM# 5699)
37. Preskorn, S. Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management. *Journal of Psychiatric Practice* 9(1), January 2003. (RM# 7289)
38. Preskorn S. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). *Journal of Psychiatric Practice* 9(2), March 2003

BOOK CHAPTERS:

1. Stanga C, Preskorn S: Use of the laboratory in psychiatry. In: *Current Psychiatric Therapy II* (ed) Dunner DL., W.B. Saunders Company, Philadelphia, Chapter 7, pp 59-74, 1997. (RM#2014)

2. Horst WD, Preskorn S: Intracellular and intercellular principles of the pharmacotherapy of patients with neuropsychiatric disorders. In: American Psychiatric Press Textbook of Neuropsychiatry, 3rd Edition. American Psychiatric Press Inc., Washington DC. Chapter 3, pp 55-75, 1997. (RM#1868)
3. Preskorn SH: Foreword. In: Primary Care Psychiatry. (ed) Knesper DJ, Riba MB, Schwenk TL. W.B. Saunders Company, Philadelphia, 1997. (RM#4557)
4. Catterson ML, Preskorn SH, Martin RL. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatric Clinics of North America. 20(1):205-218, 1997. (RM#2222)
5. Preskorn SH: Recent dose-effect studies regarding antidepressants. In: European Cooperation in the Field of Scientific and Technical Research – Compilation of Plenary Lectures. (ed) Balant LP, Benitez J, Dahl SC, Gram LF, Pinder RM, Potter WZ. European Commission, Brussels, Belgium, 1998. (RM#2724)
6. Preskorn SH, Harvey AT: Cytochrome P450 enzymes and psychopharmacology. In: Psychopharmacology: Fourth Generation of Progress - CD ROM, Version 2, 1998. Online version at <http://www.acnp.org/G4/GN401000086/Default.htm>. ACNP 2000. (RM#2251)
7. Shad M, Preskorn S: Antidepressants. In: Metabolic Drug Interactions, (eds) Levy R, Thummel K, Trager W, Hansten P, Eichelbaum M, Lippincott, Williams and Wilkins, Philadelphia, 2000. (RM#3405)
8. Preskorn SH, Catterson ML: Pharmacokinetics of Antidepressants. In: Handbook of Experimental Pharmacology. Antidepressants : Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.
9. Preskorn S: Methodological Issues in Psychopharmacogenetics. In: Pharmacogenetics of Psychotropic Drugs, (ed) Bernard Lerer, Cambridge University Press, New York, 2002. (RM#7041)
10. Preskorn S: Mood Disorders. In: Conn's Current Therapy 2003 edition, (eds.) Robert E. Rakel, Edward T. Bope, Saunders (Elsevier Science), Philadelphia, 2003. (RM#7292)
11. Preskorn SH, Khan AY: Pharmacokinetic principles and drug interactions. In: Handbook of Medical Psychiatry, (eds) Soares/Gershon, Marcel Dekker, Inc., New York, in press.
12. Preskorn SH, Catterson ML: General principles of pharmacokinetics. In: Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.

13. Preskorn SH, Burke MJ: Therapeutic drug monitoring of antidepressants. In: *Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives*, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.
14. Preskorn SH, Ross R: Overview of currently available antidepressants. In: *Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives*, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.
15. Preskorn SH, Ross R, Stanga CY: Selective serotonin reuptake inhibitors. In: *Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives*, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.
16. Preskorn SH, Ross R, Stanga CY: Other antidepressants. In: *Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives*, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.
17. Preskorn SH, Bober JF: Children and adolescents. In: *Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives*, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.
18. Preskorn SH: Role of Pharmacogenetics/pharmacogenomics in the development of new antidepressants. In: *Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives*, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.

BOOKS:

1. Janicak PG, Philip G, Davis JM, Preskorn SH, Ayd, Jr. FJ: *Principals and Practice of Psychopharmacotherapy 2nd ed.*, Williams & Wilkins, Baltimore, 1997. (2359)
2. Preskorn, S: *Outpatient Management of Depression*, Second Edition, Professional Communications, Inc., Caddo, Oklahoma, 1999. (RM#854)
3. Janicak PG, Philip G, Davis JM, Preskorn SH, Ayd, Jr. FJ: *Principals and Practice of Psychopharmacotherapy. 3rd ed.*, Lippincott Williams & Wilkins, Philadelphia, 2001. (RM#4733)
4. Preskorn SH, Catterson ML: *Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives*, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press.

ABSTRACTS:

1. Harvey A, Preskorn S. Mechanism of action of venlafaxine in normal male volunteers. *Clinical Pharmacology and Therapeutics* 61(2):175, 1997. (RM#2358)
2. Preskorn S, Shad M, Alderman J, Lane R. Fluoxetine: Age and dose dependent pharmacokinetics and CYP2C19 inhibition. *Clinical Pharmacology and Therapeutics* 63(2):166, 1998. (RM#2418)
3. Preskorn S: Central adrenergic regulation of cerebromicrocirculation: Relevance to psychiatry. *Neuropharmacology* in press. (In Press?)
4. Miceli J, Preskorn S, Wilner K, Folger C, Tensfeld T. Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. *Clinical Pharmacological Therapeutics* 65:171, 1999. (RM#2790)
5. Shad M, Carmichael C, Preskorn S, Horst W. The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. *Clinical Pharmacological Therapeutics* 65:183, 1999. (RM#2791)
6. Preskorn, S H. Pharmacogenetic research in clinical psychopharmacology: Design and methodological challenges. *International Journal of Neuropsychopharmacology* 3(Suppl 1):5, 2000. (RM#4190)
7. Silkey B, Preskorn S, Golbeck A, Horst W. Addressing health risks/costs associated with multiple medication use in a veterans integrated service network. Poster presentation at Drug Information Association 2nd Annual Workshop on "Pharmaceutical Outcomes Research," Seattle, Washington, May 11-12, 2000. (RM#3913)
8. Silkey B, Preskorn S, Golbeck A. Interindividual variability in steady-state plasma levels of bupropion and its major metabolites. Poster presentation at 40th Annual NCDEU, Boca Raton, Florida, May 30-June 2, 2000. (RM#4050)
9. Reyes LF, Preskorn S, Khan A, Kumar S, Cullen E, Pratt R. Pharmacokinetics (PK) of donepezil and risperidone in males with schizophrenia. *Clinical Pharmacology and Therapeutics* 69:44, 2001. (RM#4888)
10. Harvey A, Preskorn SH. The influence of extended-release venlafaxine on QT intervals of normal volunteers. Poster presentation at NCDEU 41st Annual Meeting, Phoenix, Arizona, May 28-31, 2001. (RM#5534)
11. Khan A, Friesen S, Klick-Davis A, Preskorn SH. How inclusion and exclusion criteria affect the ability to randomize patients in a clinical trial for schizophrenia/schizo-affective disorder. Poster presentation at NCDEU 41st Annual Meeting, Phoenix, Arizona, May 28-31, 2001. (RM#5536)

12. Preskorn SH, Baker B. The clinical pharmacology of antidepressants: Relevance to the optimum management of the depressed patient. Poster presentation at AANP 2001. (RM#5537)
13. Harvey A, Preskorn SH. The influence of intramuscular (IM) haloperidol (HAL) or lorazepam (LOR) on QT intervals of volunteers with schizophrenia. *Clinical Pharmacology and Therapeutics* 71(2), P53, 2002. (RM#5114)
14. Preskorn SH, Silkey B, Shar R, Neff M. Multiple medication use and cytochrome P-450-based drug interaction patterns in patients on antidepressants in a regional veterans affairs health care network. *Clinical Pharmacology and Therapeutics* 71(2), P59, 2002. (RM#5596)
15. Wesnes KA, Preskorn SH, Friesen S, Edgar C, Mikkelsen BO. NS 2330 enhances cognitive function in normal volunteers and volunteers with possible Alzheimer's disease (AD). *Clinical Pharmacology and Therapeutics* 71(2), P17, 2002. (RM#5597)

LETTERS TO THE EDITOR:

1. Preskorn SH, Baker B: Fatality associated with combined fluoxetine-amitriptyline therapy. *Journal of American Medical Association* 277(21):682, 1997. (RM#2736)
2. Shad MU, Preskorn SH: A possible bupropion and imipramine interaction. *Journal of Clinical Psychopharmacology* 17(2):118, 1997. (RM#2197)
3. Shad MU, Preskorn SH: Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome. *Journal of Clinical Psychopharmacology* 18(4):346-347, 1998. (RM#2730)
4. Shad MU, Preskorn SH. Drug-drug interaction in reverse: Possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. *Journal of Clinical Psychopharmacology* 19(5):471-472, 1999. (RM#3155)
5. Shad MU, Preskorn SH, Izgur Z: Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder. *Journal of Clinical Psychiatry* 20(3):390-391, 2000. (RM#4113)
6. Khan A, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. *Journal of Clinical Psychiatry* 61(7):526-527, 2000. (RM#3844)
7. Preskorn SH, Greenblatt DJ, Harvey AT. Lack of effect of sertraline on the pharmacokinetics of alprazolam. *Journal of Clinical Psychopharmacology* 20(5):585-586, 2000. (RM#4694)

8. Khan AY, Preskorn, SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. *Journal of Clinical Psychiatry* 62(5), 375-376. (RM#5123)
9. Shad, Marsh, C, Preskorn, SH. The economic consequences of a drug-drug interaction. *Journal of Clinical Psychopharmacology* 21(1):119-20, 2001 Feb. 2002 (RM#4137)

PUBLISHED INTERVIEWS:

1. Preskorn SH: Pharmacokinetic interactivity of psychotropic drugs. Part I. Currents in Affective Illness, (eds) Rosenblatt JE, Rosenblatt NC, 17:4,4 April, 1998.
2. Preskorn SH: Pharmacokinetic interactivity of psychotropic drugs-conclusion. Currents in Affective Illness, (eds) Rosenblatt JE, Rosenblatt NC, 17:5,5 May, 1998.
3. Preskorn SH: New paradigms for drug development. Part I. Currents in Affective Illness, (eds) Rosenblatt JE, Rosenblatt NC, 20:3; 5-11 March, 2001 (RM#4989)
4. Preskorn SH: New paradigms for drug development. Part II. Currents in Affective Illness, (eds) Rosenblatt JE, Rosenblatt NC, 20:4; 5-9 April, 2001 (RM#4990)

EDITOR OF JOURNAL SUPPLEMENTS:

Sertraline: A pharmacokinetic profile. Journal of Clinical Pharmacokinetics. 32 (Suppl 1), 1997.

SLIDE KITS:

Preskorn S: Pharmacokinetics and psychiatric medicine: Optimizing efficacy, safety, and cost effectiveness. Current Medical Directions, New York, New York, 1997.

PSYCHIATRY VIDEOTAPES:

Preskorn S: Selegiline patch-depression with Sahar El-Hodiri. May 22, 1997.

PUBLIC AFFAIRS:

“Live at Five”. An interview on prime time television concerning depression in general, November, 1997.

“Family Health Channel, Focus on Depression. An interview concerning depression, 1998.

SPECIAL PRESENTATIONS:

Visiting Professor for Annual Psychopharmacology Day:

1997-University of Toronto in Toronto, Ontario, Canada

1998-University of Alberta in Edmonton, Alberta, Canada

1999-University of Hamilton in Hamilton, Ontario, Canada

Sept. 14, 2002 – German Neuroscience Academy in Versailles, France. “Drug development in psychiatry and the human genome project: Implications for clinical practice.”

Oct. 2, 2002 – Keynote address at Annual Psychopharmacology Update Program for the University of Oklahoma at Tulsa. “Drug-drug interactions: Their mechanisms, their clinical presentation, and their clinical relevance.”

Oct. 6, 2002 – Keynote address at Annual Psychopharmacology Update Program for the University of Mississippi in Jacksonville, MS. “The rational basis for the combined use of more than one psychiatric medication.”